MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors ... View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2019-12

AUTHORS

Yoshimi Endo Greer, Samuel F. Gilbert, Brunilde Gril, Rajesh Narwal, Danielle L. Peacock Brooks, David A. Tice, Patricia S. Steeg, Stanley Lipkowitz

ABSTRACT

BACKGROUND: TNF-related apoptosis-inducing ligand (TRAIL) receptor agonists are attractive anti-tumor agents because of their capability to induce apoptosis in cancer cells by activating death receptors (DR) 4 and 5 with little toxicity against normal cells. Despite an attractive mechanism of action, previous clinical efforts to use TRAIL receptor agonists have been unsuccessful. In this study, we examined MEDI3039, a highly potent multivalent DR5 agonist, in breast cancer cell lines and in vivo models. METHODS: As in vitro model systems, we used 19 breast cancer cell lines that are categorized into four subtypes: ER+, HER2 amplified, basal A (triple-negative breast cancer) TNBC, and basal B TNBC. Cell viability was analyzed by MTS and RealTime live/dead assays. As in vivo model systems, MDA-MB231T orthotopic primary tumor growth in the mammary fat pad (MFP) and two experimental lung metastasis models were used. The effect of MEDI3039 on MFP tumors was assessed with immunohistochemical analysis. Lung metastases were analyzed with Bouin's and H&E staining. RESULTS: MEDI3039 killed multiple breast cancer cell lines, but the sensitivity varied among different subtypes. Sensitivity was basal B TNBC >> basal A TNBC > HER2 amplified > ER+ (average IC50 = 1.4, 203, 314, 403 pM, respectively). While the pattern of relative sensitivity was similar to GST-TRAIL in most cell lines, MEDI3039 was at least two orders of magnitude more potent compared with GST-TRAIL. In the MFP model, weekly treatment with 0.1 or 0.3 mg/kg MEDI3039 for 5 weeks inhibited tumor growth by 99.05% or 100% (median), respectively, compared with the control group, and extended animal survival (p = 0.08 or p = 0.0032 at 0.1 or 0.3 mg/kg, respectively). MEDI3039-induced caspase activation was confirmed in tumors grown in MFP (p < 0.05). In an experimental pulmonary metastasis model, MEDI3039 significantly suppressed outgrowth of surface (p < 0.0001) and microscopic metastases (p < 0.05). In an established lung metastasis model, MEDI3039 significantly inhibited growth of metastases (p < 0.01 in surface [> 4 mm], p < 0.01 in tumor percentage) and extended animal survival (p < 0.0001). CONCLUSION: MEDI3039 is a potent DR5 agonist in breast cancer cells in vitro and in vivo and has potential as a cancer drug in breast cancer patients, especially those with basal B TNBC. More... »

PAGES

27

References to SciGraph publications

  • 2016-01. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl in BREAST CANCER RESEARCH AND TREATMENT
  • 2010-08. New insights into apoptosis signaling by Apo2L/TRAIL in ONCOGENE
  • 2009-05. Systems biology: When it is time to die in NATURE
  • 2005-11. Biomarkers in Cancer Staging, Prognosis and Treatment Selection in NATURE REVIEWS CANCER
  • 2000-08. Molecular portraits of human breast tumours in NATURE
  • 2016-11. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease in NATURE REVIEWS CLINICAL ONCOLOGY
  • 2011-12. Evaluation of pharmacodynamic biomarkers in a Phase 1a trial of dulanermin (rhApo2L/TRAIL) in patients with advanced tumours in BRITISH JOURNAL OF CANCER
  • 2009-05. Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis in NATURE
  • 2008-04. Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 in CELL DEATH & DIFFERENTIATION
  • 2010-07. Identification of WEE1 as a potential molecular target in cancer cells by RNAi screening of the human tyrosine kinome in BREAST CANCER RESEARCH AND TREATMENT
  • 2011-10. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL in BREAST CANCER RESEARCH
  • 2009-01. TRAIL induces apoptosis in triple-negative breast cancer cells with a mesenchymal phenotype in BREAST CANCER RESEARCH AND TREATMENT
  • 2012-09-23. Comprehensive molecular portraits of human breast tumours in NATURE
  • Identifiers

    URI

    http://scigraph.springernature.com/pub.10.1186/s13058-019-1116-1

    DOI

    http://dx.doi.org/10.1186/s13058-019-1116-1

    DIMENSIONS

    https://app.dimensions.ai/details/publication/pub.1112212889

    PUBMED

    https://www.ncbi.nlm.nih.gov/pubmed/30777098


    Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
    Incoming Citations Browse incoming citations for this publication using opencitations.net

    JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Oncology and Carcinogenesis", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "name": "Medical and Health Sciences", 
            "type": "DefinedTerm"
          }
        ], 
        "author": [
          {
            "affiliation": {
              "alternateName": "Center for Cancer Research", 
              "id": "https://www.grid.ac/institutes/grid.417768.b", 
              "name": [
                "Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4B54, 20892-1361, Bethesda, MD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Greer", 
            "givenName": "Yoshimi Endo", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Center for Cancer Research", 
              "id": "https://www.grid.ac/institutes/grid.417768.b", 
              "name": [
                "Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4B54, 20892-1361, Bethesda, MD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gilbert", 
            "givenName": "Samuel F.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Center for Cancer Research", 
              "id": "https://www.grid.ac/institutes/grid.417768.b", 
              "name": [
                "Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4B54, 20892-1361, Bethesda, MD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Gril", 
            "givenName": "Brunilde", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "AstraZeneca (United States)", 
              "id": "https://www.grid.ac/institutes/grid.418152.b", 
              "name": [
                "MedImmune, LLC, Gaithersburg, MD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Narwal", 
            "givenName": "Rajesh", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Center for Cancer Research", 
              "id": "https://www.grid.ac/institutes/grid.417768.b", 
              "name": [
                "Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4B54, 20892-1361, Bethesda, MD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Peacock Brooks", 
            "givenName": "Danielle L.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "AstraZeneca (United States)", 
              "id": "https://www.grid.ac/institutes/grid.418152.b", 
              "name": [
                "MedImmune, LLC, Gaithersburg, MD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Tice", 
            "givenName": "David A.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Center for Cancer Research", 
              "id": "https://www.grid.ac/institutes/grid.417768.b", 
              "name": [
                "Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4B54, 20892-1361, Bethesda, MD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Steeg", 
            "givenName": "Patricia S.", 
            "type": "Person"
          }, 
          {
            "affiliation": {
              "alternateName": "Center for Cancer Research", 
              "id": "https://www.grid.ac/institutes/grid.417768.b", 
              "name": [
                "Women\u2019s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4B54, 20892-1361, Bethesda, MD, USA"
              ], 
              "type": "Organization"
            }, 
            "familyName": "Lipkowitz", 
            "givenName": "Stanley", 
            "type": "Person"
          }
        ], 
        "citation": [
          {
            "id": "https://doi.org/10.1016/j.molonc.2010.11.003", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1000679392"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1078-0432.ccr-11-0099", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1002263531"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10549-008-9924-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004175549", 
              "https://doi.org/10.1007/s10549-008-9924-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10549-008-9924-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1004175549", 
              "https://doi.org/10.1007/s10549-008-9924-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1535-7163.mct-12-1107", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1007777257"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.molcel.2009.05.001", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1009338658"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/bjc.2011.456", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1010106674", 
              "https://doi.org/10.1038/bjc.2011.456"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrclinonc.2016.66", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1011587927", 
              "https://doi.org/10.1038/nrclinonc.2016.66"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/jnci/dji111", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1012123441"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1078-0432.ccr-14-2780", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1018580324"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1517/14728222.2010.519701", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019091862"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2009.25.1991", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019828190"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/sj.cdd.4402306", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1019980757", 
              "https://doi.org/10.1038/sj.cdd.4402306"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1172/jci80420", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1022292043"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1078-0432.ccr-09-1692", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024329711"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature11412", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1024942368", 
              "https://doi.org/10.1038/nature11412"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0065-230x(06)96008-4", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1028038077"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1186/bcr2945", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030462236", 
              "https://doi.org/10.1186/bcr2945"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/gco.0000000000000239", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033356012"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1097/gco.0000000000000239", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033356012"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.ccr.2014.04.028", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033537828"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.ccr.2014.04.028", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033537828"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/35021093", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1033846543", 
              "https://doi.org/10.1038/35021093"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1146/annurev-bioeng-112415-114722", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1035945779"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/459334a", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036855676", 
              "https://doi.org/10.1038/459334a"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/459334a", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1036855676", 
              "https://doi.org/10.1038/459334a"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1172/jci45014", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1037799511"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/s0065-230x(09)03003-6", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1038528751"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1371/journal.pone.0075414", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1039471372"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.ccr.2006.10.008", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1040586971"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10549-015-3673-z", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043457677", 
              "https://doi.org/10.1007/s10549-015-3673-z"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/onc.2010.221", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043860701", 
              "https://doi.org/10.1038/onc.2010.221"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/onc.2010.221", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1043860701", 
              "https://doi.org/10.1038/onc.2010.221"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1093/annonc/mdn015", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1046245271"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1739", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048794721", 
              "https://doi.org/10.1038/nrc1739"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1739", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048794721", 
              "https://doi.org/10.1038/nrc1739"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nrc1739", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1048794721", 
              "https://doi.org/10.1038/nrc1739"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature08012", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050616550", 
              "https://doi.org/10.1038/nature08012"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1038/nature08012", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1050616550", 
              "https://doi.org/10.1038/nature08012"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "sg:pub.10.1007/s10549-009-0571-2", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1051612647", 
              "https://doi.org/10.1007/s10549-009-0571-2"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1016/j.cytogfr.2013.12.009", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1052221635"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1074/jbc.m115.713545", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1058214598"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1089/ten.tea.2010.0273", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1059315652"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1126/science.1279805", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1062471450"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1200/jco.2005.03.3845", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1064204218"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1517/14712590903319656", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1067588039"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.4161/cbt.6.9.4905", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1072294727"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://app.dimensions.ai/details/publication/pub.1074882356", 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.4049/jimmunol.170.9.4854", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1075280428"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1158/1078-0432.ccr-17-1029", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1091249666"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.7554/elife.30224", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1100468486"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.7554/elife.30224", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1100468486"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1111/his.13528", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1103268269"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "datePublished": "2019-12", 
        "datePublishedReg": "2019-12-01", 
        "description": "BACKGROUND: TNF-related apoptosis-inducing ligand (TRAIL) receptor agonists are attractive anti-tumor agents because of their capability to induce apoptosis in cancer cells by activating death receptors (DR) 4 and 5 with little toxicity against normal cells. Despite an attractive mechanism of action, previous clinical efforts to use TRAIL receptor agonists have been unsuccessful. In this study, we examined MEDI3039, a highly potent multivalent DR5 agonist, in breast cancer cell lines and in vivo models.\nMETHODS: As in vitro model systems, we used 19 breast cancer cell lines that are categorized into four subtypes: ER+, HER2 amplified, basal A (triple-negative breast cancer) TNBC, and basal B TNBC. Cell viability was analyzed by MTS and RealTime live/dead assays. As in vivo model systems, MDA-MB231T orthotopic primary tumor growth in the mammary fat pad (MFP) and two experimental lung metastasis models were used. The effect of MEDI3039 on MFP tumors was assessed with immunohistochemical analysis. Lung metastases were analyzed with Bouin's and H&E staining.\nRESULTS: MEDI3039 killed multiple breast cancer cell lines, but the sensitivity varied among different subtypes. Sensitivity was basal B TNBC >> basal A TNBC > HER2 amplified > ER+ (average IC50\u2009=\u20091.4, 203, 314, 403\u2009pM, respectively). While the pattern of relative sensitivity was similar to GST-TRAIL in most cell lines, MEDI3039 was at least two orders of magnitude more potent compared with GST-TRAIL. In the MFP model, weekly treatment with 0.1 or 0.3\u2009mg/kg MEDI3039 for 5\u2009weeks inhibited tumor growth by 99.05% or 100% (median), respectively, compared with the control group, and extended animal survival (p\u2009=\u20090.08 or p\u2009=\u20090.0032 at 0.1 or 0.3\u2009mg/kg, respectively). MEDI3039-induced caspase activation was confirmed in tumors grown in MFP (p\u2009<\u20090.05). In an experimental pulmonary metastasis model, MEDI3039 significantly suppressed outgrowth of surface (p\u2009<\u20090.0001) and microscopic metastases (p\u2009<\u20090.05). In an established lung metastasis model, MEDI3039 significantly inhibited growth of metastases (p\u2009<\u20090.01 in surface [>\u20094\u2009mm], p\u2009<\u20090.01 in tumor percentage) and extended animal survival (p\u2009<\u20090.0001).\nCONCLUSION: MEDI3039 is a potent DR5 agonist in breast cancer cells in vitro and in vivo and has potential as a cancer drug in breast cancer patients, especially those with basal B TNBC.", 
        "genre": "research_article", 
        "id": "sg:pub.10.1186/s13058-019-1116-1", 
        "inLanguage": [
          "en"
        ], 
        "isAccessibleForFree": true, 
        "isFundedItemOf": [
          {
            "id": "sg:grant.2722431", 
            "type": "MonetaryGrant"
          }, 
          {
            "id": "sg:grant.2726375", 
            "type": "MonetaryGrant"
          }
        ], 
        "isPartOf": [
          {
            "id": "sg:journal.1022375", 
            "issn": [
              "1465-5411", 
              "1465-542X"
            ], 
            "name": "Breast Cancer Research", 
            "type": "Periodical"
          }, 
          {
            "issueNumber": "1", 
            "type": "PublicationIssue"
          }, 
          {
            "type": "PublicationVolume", 
            "volumeNumber": "21"
          }
        ], 
        "name": "MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer", 
        "pagination": "27", 
        "productId": [
          {
            "name": "readcube_id", 
            "type": "PropertyValue", 
            "value": [
              "14a8cf5ce08720a4c6cc4f6512e302e9b078b9497f084585ce9de52031d28587"
            ]
          }, 
          {
            "name": "pubmed_id", 
            "type": "PropertyValue", 
            "value": [
              "30777098"
            ]
          }, 
          {
            "name": "nlm_unique_id", 
            "type": "PropertyValue", 
            "value": [
              "100927353"
            ]
          }, 
          {
            "name": "doi", 
            "type": "PropertyValue", 
            "value": [
              "10.1186/s13058-019-1116-1"
            ]
          }, 
          {
            "name": "dimensions_id", 
            "type": "PropertyValue", 
            "value": [
              "pub.1112212889"
            ]
          }
        ], 
        "sameAs": [
          "https://doi.org/10.1186/s13058-019-1116-1", 
          "https://app.dimensions.ai/details/publication/pub.1112212889"
        ], 
        "sdDataset": "articles", 
        "sdDatePublished": "2019-04-11T11:38", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000358_0000000358/records_127432_00000011.jsonl", 
        "type": "ScholarlyArticle", 
        "url": "https://link.springer.com/10.1186%2Fs13058-019-1116-1"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1186/s13058-019-1116-1'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1186/s13058-019-1116-1'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1186/s13058-019-1116-1'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1186/s13058-019-1116-1'


     

    This table displays all metadata directly associated to this object as RDF triples.

    261 TRIPLES      21 PREDICATES      73 URIs      21 LITERALS      9 BLANK NODES

    Subject Predicate Object
    1 sg:pub.10.1186/s13058-019-1116-1 schema:about anzsrc-for:11
    2 anzsrc-for:1112
    3 schema:author N6d0cd23809e147e0be977ec6fa27c164
    4 schema:citation sg:pub.10.1007/s10549-008-9924-5
    5 sg:pub.10.1007/s10549-009-0571-2
    6 sg:pub.10.1007/s10549-015-3673-z
    7 sg:pub.10.1038/35021093
    8 sg:pub.10.1038/459334a
    9 sg:pub.10.1038/bjc.2011.456
    10 sg:pub.10.1038/nature08012
    11 sg:pub.10.1038/nature11412
    12 sg:pub.10.1038/nrc1739
    13 sg:pub.10.1038/nrclinonc.2016.66
    14 sg:pub.10.1038/onc.2010.221
    15 sg:pub.10.1038/sj.cdd.4402306
    16 sg:pub.10.1186/bcr2945
    17 https://app.dimensions.ai/details/publication/pub.1074882356
    18 https://doi.org/10.1016/j.ccr.2006.10.008
    19 https://doi.org/10.1016/j.ccr.2014.04.028
    20 https://doi.org/10.1016/j.cytogfr.2013.12.009
    21 https://doi.org/10.1016/j.molcel.2009.05.001
    22 https://doi.org/10.1016/j.molonc.2010.11.003
    23 https://doi.org/10.1016/s0065-230x(06)96008-4
    24 https://doi.org/10.1016/s0065-230x(09)03003-6
    25 https://doi.org/10.1074/jbc.m115.713545
    26 https://doi.org/10.1089/ten.tea.2010.0273
    27 https://doi.org/10.1093/annonc/mdn015
    28 https://doi.org/10.1093/jnci/dji111
    29 https://doi.org/10.1097/gco.0000000000000239
    30 https://doi.org/10.1111/his.13528
    31 https://doi.org/10.1126/science.1279805
    32 https://doi.org/10.1146/annurev-bioeng-112415-114722
    33 https://doi.org/10.1158/1078-0432.ccr-09-1692
    34 https://doi.org/10.1158/1078-0432.ccr-11-0099
    35 https://doi.org/10.1158/1078-0432.ccr-14-2780
    36 https://doi.org/10.1158/1078-0432.ccr-17-1029
    37 https://doi.org/10.1158/1535-7163.mct-12-1107
    38 https://doi.org/10.1172/jci45014
    39 https://doi.org/10.1172/jci80420
    40 https://doi.org/10.1200/jco.2005.03.3845
    41 https://doi.org/10.1200/jco.2009.25.1991
    42 https://doi.org/10.1371/journal.pone.0075414
    43 https://doi.org/10.1517/14712590903319656
    44 https://doi.org/10.1517/14728222.2010.519701
    45 https://doi.org/10.4049/jimmunol.170.9.4854
    46 https://doi.org/10.4161/cbt.6.9.4905
    47 https://doi.org/10.7554/elife.30224
    48 schema:datePublished 2019-12
    49 schema:datePublishedReg 2019-12-01
    50 schema:description BACKGROUND: TNF-related apoptosis-inducing ligand (TRAIL) receptor agonists are attractive anti-tumor agents because of their capability to induce apoptosis in cancer cells by activating death receptors (DR) 4 and 5 with little toxicity against normal cells. Despite an attractive mechanism of action, previous clinical efforts to use TRAIL receptor agonists have been unsuccessful. In this study, we examined MEDI3039, a highly potent multivalent DR5 agonist, in breast cancer cell lines and in vivo models. METHODS: As in vitro model systems, we used 19 breast cancer cell lines that are categorized into four subtypes: ER+, HER2 amplified, basal A (triple-negative breast cancer) TNBC, and basal B TNBC. Cell viability was analyzed by MTS and RealTime live/dead assays. As in vivo model systems, MDA-MB231T orthotopic primary tumor growth in the mammary fat pad (MFP) and two experimental lung metastasis models were used. The effect of MEDI3039 on MFP tumors was assessed with immunohistochemical analysis. Lung metastases were analyzed with Bouin's and H&E staining. RESULTS: MEDI3039 killed multiple breast cancer cell lines, but the sensitivity varied among different subtypes. Sensitivity was basal B TNBC >> basal A TNBC > HER2 amplified > ER+ (average IC50 = 1.4, 203, 314, 403 pM, respectively). While the pattern of relative sensitivity was similar to GST-TRAIL in most cell lines, MEDI3039 was at least two orders of magnitude more potent compared with GST-TRAIL. In the MFP model, weekly treatment with 0.1 or 0.3 mg/kg MEDI3039 for 5 weeks inhibited tumor growth by 99.05% or 100% (median), respectively, compared with the control group, and extended animal survival (p = 0.08 or p = 0.0032 at 0.1 or 0.3 mg/kg, respectively). MEDI3039-induced caspase activation was confirmed in tumors grown in MFP (p < 0.05). In an experimental pulmonary metastasis model, MEDI3039 significantly suppressed outgrowth of surface (p < 0.0001) and microscopic metastases (p < 0.05). In an established lung metastasis model, MEDI3039 significantly inhibited growth of metastases (p < 0.01 in surface [> 4 mm], p < 0.01 in tumor percentage) and extended animal survival (p < 0.0001). CONCLUSION: MEDI3039 is a potent DR5 agonist in breast cancer cells in vitro and in vivo and has potential as a cancer drug in breast cancer patients, especially those with basal B TNBC.
    51 schema:genre research_article
    52 schema:inLanguage en
    53 schema:isAccessibleForFree true
    54 schema:isPartOf N3720639e09de4a7fa5b8112b60f6a74e
    55 Nb7181207b53d4fdf9421ee57b27fd0a8
    56 sg:journal.1022375
    57 schema:name MEDI3039, a novel highly potent tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptor 2 agonist, causes regression of orthotopic tumors and inhibits outgrowth of metastatic triple-negative breast cancer
    58 schema:pagination 27
    59 schema:productId N0a53898958254f34a78a2c438e692bac
    60 N148424cabcdd44da8bd5098cff40a720
    61 Na38a961c9d364a39835e0f595581bee2
    62 Nfc7341595dd7465d8ccc28bd36ee53c7
    63 Nfc7a84ae46f540de8258936606aeb5d1
    64 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112212889
    65 https://doi.org/10.1186/s13058-019-1116-1
    66 schema:sdDatePublished 2019-04-11T11:38
    67 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    68 schema:sdPublisher Ncf2faeb5414446b4bbcbf2c0b4abf006
    69 schema:url https://link.springer.com/10.1186%2Fs13058-019-1116-1
    70 sgo:license sg:explorer/license/
    71 sgo:sdDataset articles
    72 rdf:type schema:ScholarlyArticle
    73 N03a015d53a7443aaad1675a4c8028575 rdf:first N446a63271c4841ddb9214d030b6a9af2
    74 rdf:rest N6ff8493691a04e28a5b95e4117943fc2
    75 N05533180309a4fe1ac9ba4a384a439dd schema:affiliation https://www.grid.ac/institutes/grid.417768.b
    76 schema:familyName Steeg
    77 schema:givenName Patricia S.
    78 rdf:type schema:Person
    79 N0a53898958254f34a78a2c438e692bac schema:name doi
    80 schema:value 10.1186/s13058-019-1116-1
    81 rdf:type schema:PropertyValue
    82 N148424cabcdd44da8bd5098cff40a720 schema:name pubmed_id
    83 schema:value 30777098
    84 rdf:type schema:PropertyValue
    85 N17680eaa7b9b4b3cb3b6596be1873ecf rdf:first N3d3d1b3af9fc478281f14ab5f3a7c4f6
    86 rdf:rest N03a015d53a7443aaad1675a4c8028575
    87 N3720639e09de4a7fa5b8112b60f6a74e schema:volumeNumber 21
    88 rdf:type schema:PublicationVolume
    89 N3d3d1b3af9fc478281f14ab5f3a7c4f6 schema:affiliation https://www.grid.ac/institutes/grid.417768.b
    90 schema:familyName Gril
    91 schema:givenName Brunilde
    92 rdf:type schema:Person
    93 N438ef406eafd487c8d1e527e25e1c0b5 schema:affiliation https://www.grid.ac/institutes/grid.417768.b
    94 schema:familyName Lipkowitz
    95 schema:givenName Stanley
    96 rdf:type schema:Person
    97 N446a63271c4841ddb9214d030b6a9af2 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
    98 schema:familyName Narwal
    99 schema:givenName Rajesh
    100 rdf:type schema:Person
    101 N58638cf6a63f4601af13e049954cb485 schema:affiliation https://www.grid.ac/institutes/grid.418152.b
    102 schema:familyName Tice
    103 schema:givenName David A.
    104 rdf:type schema:Person
    105 N5df005ec8cf64b919540084fc90406fc rdf:first N438ef406eafd487c8d1e527e25e1c0b5
    106 rdf:rest rdf:nil
    107 N6d0cd23809e147e0be977ec6fa27c164 rdf:first Nd18024c5c3bf4a7098ef5a6b69bca593
    108 rdf:rest N77a84c3feec9470aa0d3082dc5bf1925
    109 N6ff8493691a04e28a5b95e4117943fc2 rdf:first N7187da5e4a3d4a2286e44cf997214012
    110 rdf:rest N9228ab738bc747e19af1b4104db4d6d8
    111 N7187da5e4a3d4a2286e44cf997214012 schema:affiliation https://www.grid.ac/institutes/grid.417768.b
    112 schema:familyName Peacock Brooks
    113 schema:givenName Danielle L.
    114 rdf:type schema:Person
    115 N77a84c3feec9470aa0d3082dc5bf1925 rdf:first Nd1242c8ca1ed401b9e412efe9fbc593d
    116 rdf:rest N17680eaa7b9b4b3cb3b6596be1873ecf
    117 N9228ab738bc747e19af1b4104db4d6d8 rdf:first N58638cf6a63f4601af13e049954cb485
    118 rdf:rest N999caa976a904cdd8a41738bb9a885fe
    119 N999caa976a904cdd8a41738bb9a885fe rdf:first N05533180309a4fe1ac9ba4a384a439dd
    120 rdf:rest N5df005ec8cf64b919540084fc90406fc
    121 Na38a961c9d364a39835e0f595581bee2 schema:name dimensions_id
    122 schema:value pub.1112212889
    123 rdf:type schema:PropertyValue
    124 Nb7181207b53d4fdf9421ee57b27fd0a8 schema:issueNumber 1
    125 rdf:type schema:PublicationIssue
    126 Ncf2faeb5414446b4bbcbf2c0b4abf006 schema:name Springer Nature - SN SciGraph project
    127 rdf:type schema:Organization
    128 Nd1242c8ca1ed401b9e412efe9fbc593d schema:affiliation https://www.grid.ac/institutes/grid.417768.b
    129 schema:familyName Gilbert
    130 schema:givenName Samuel F.
    131 rdf:type schema:Person
    132 Nd18024c5c3bf4a7098ef5a6b69bca593 schema:affiliation https://www.grid.ac/institutes/grid.417768.b
    133 schema:familyName Greer
    134 schema:givenName Yoshimi Endo
    135 rdf:type schema:Person
    136 Nfc7341595dd7465d8ccc28bd36ee53c7 schema:name readcube_id
    137 schema:value 14a8cf5ce08720a4c6cc4f6512e302e9b078b9497f084585ce9de52031d28587
    138 rdf:type schema:PropertyValue
    139 Nfc7a84ae46f540de8258936606aeb5d1 schema:name nlm_unique_id
    140 schema:value 100927353
    141 rdf:type schema:PropertyValue
    142 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
    143 schema:name Medical and Health Sciences
    144 rdf:type schema:DefinedTerm
    145 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
    146 schema:name Oncology and Carcinogenesis
    147 rdf:type schema:DefinedTerm
    148 sg:grant.2722431 http://pending.schema.org/fundedItem sg:pub.10.1186/s13058-019-1116-1
    149 rdf:type schema:MonetaryGrant
    150 sg:grant.2726375 http://pending.schema.org/fundedItem sg:pub.10.1186/s13058-019-1116-1
    151 rdf:type schema:MonetaryGrant
    152 sg:journal.1022375 schema:issn 1465-5411
    153 1465-542X
    154 schema:name Breast Cancer Research
    155 rdf:type schema:Periodical
    156 sg:pub.10.1007/s10549-008-9924-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004175549
    157 https://doi.org/10.1007/s10549-008-9924-5
    158 rdf:type schema:CreativeWork
    159 sg:pub.10.1007/s10549-009-0571-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051612647
    160 https://doi.org/10.1007/s10549-009-0571-2
    161 rdf:type schema:CreativeWork
    162 sg:pub.10.1007/s10549-015-3673-z schema:sameAs https://app.dimensions.ai/details/publication/pub.1043457677
    163 https://doi.org/10.1007/s10549-015-3673-z
    164 rdf:type schema:CreativeWork
    165 sg:pub.10.1038/35021093 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033846543
    166 https://doi.org/10.1038/35021093
    167 rdf:type schema:CreativeWork
    168 sg:pub.10.1038/459334a schema:sameAs https://app.dimensions.ai/details/publication/pub.1036855676
    169 https://doi.org/10.1038/459334a
    170 rdf:type schema:CreativeWork
    171 sg:pub.10.1038/bjc.2011.456 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010106674
    172 https://doi.org/10.1038/bjc.2011.456
    173 rdf:type schema:CreativeWork
    174 sg:pub.10.1038/nature08012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050616550
    175 https://doi.org/10.1038/nature08012
    176 rdf:type schema:CreativeWork
    177 sg:pub.10.1038/nature11412 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024942368
    178 https://doi.org/10.1038/nature11412
    179 rdf:type schema:CreativeWork
    180 sg:pub.10.1038/nrc1739 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048794721
    181 https://doi.org/10.1038/nrc1739
    182 rdf:type schema:CreativeWork
    183 sg:pub.10.1038/nrclinonc.2016.66 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011587927
    184 https://doi.org/10.1038/nrclinonc.2016.66
    185 rdf:type schema:CreativeWork
    186 sg:pub.10.1038/onc.2010.221 schema:sameAs https://app.dimensions.ai/details/publication/pub.1043860701
    187 https://doi.org/10.1038/onc.2010.221
    188 rdf:type schema:CreativeWork
    189 sg:pub.10.1038/sj.cdd.4402306 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019980757
    190 https://doi.org/10.1038/sj.cdd.4402306
    191 rdf:type schema:CreativeWork
    192 sg:pub.10.1186/bcr2945 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030462236
    193 https://doi.org/10.1186/bcr2945
    194 rdf:type schema:CreativeWork
    195 https://app.dimensions.ai/details/publication/pub.1074882356 schema:CreativeWork
    196 https://doi.org/10.1016/j.ccr.2006.10.008 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040586971
    197 rdf:type schema:CreativeWork
    198 https://doi.org/10.1016/j.ccr.2014.04.028 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033537828
    199 rdf:type schema:CreativeWork
    200 https://doi.org/10.1016/j.cytogfr.2013.12.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1052221635
    201 rdf:type schema:CreativeWork
    202 https://doi.org/10.1016/j.molcel.2009.05.001 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009338658
    203 rdf:type schema:CreativeWork
    204 https://doi.org/10.1016/j.molonc.2010.11.003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000679392
    205 rdf:type schema:CreativeWork
    206 https://doi.org/10.1016/s0065-230x(06)96008-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028038077
    207 rdf:type schema:CreativeWork
    208 https://doi.org/10.1016/s0065-230x(09)03003-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038528751
    209 rdf:type schema:CreativeWork
    210 https://doi.org/10.1074/jbc.m115.713545 schema:sameAs https://app.dimensions.ai/details/publication/pub.1058214598
    211 rdf:type schema:CreativeWork
    212 https://doi.org/10.1089/ten.tea.2010.0273 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059315652
    213 rdf:type schema:CreativeWork
    214 https://doi.org/10.1093/annonc/mdn015 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046245271
    215 rdf:type schema:CreativeWork
    216 https://doi.org/10.1093/jnci/dji111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012123441
    217 rdf:type schema:CreativeWork
    218 https://doi.org/10.1097/gco.0000000000000239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033356012
    219 rdf:type schema:CreativeWork
    220 https://doi.org/10.1111/his.13528 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103268269
    221 rdf:type schema:CreativeWork
    222 https://doi.org/10.1126/science.1279805 schema:sameAs https://app.dimensions.ai/details/publication/pub.1062471450
    223 rdf:type schema:CreativeWork
    224 https://doi.org/10.1146/annurev-bioeng-112415-114722 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035945779
    225 rdf:type schema:CreativeWork
    226 https://doi.org/10.1158/1078-0432.ccr-09-1692 schema:sameAs https://app.dimensions.ai/details/publication/pub.1024329711
    227 rdf:type schema:CreativeWork
    228 https://doi.org/10.1158/1078-0432.ccr-11-0099 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002263531
    229 rdf:type schema:CreativeWork
    230 https://doi.org/10.1158/1078-0432.ccr-14-2780 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018580324
    231 rdf:type schema:CreativeWork
    232 https://doi.org/10.1158/1078-0432.ccr-17-1029 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091249666
    233 rdf:type schema:CreativeWork
    234 https://doi.org/10.1158/1535-7163.mct-12-1107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007777257
    235 rdf:type schema:CreativeWork
    236 https://doi.org/10.1172/jci45014 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037799511
    237 rdf:type schema:CreativeWork
    238 https://doi.org/10.1172/jci80420 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022292043
    239 rdf:type schema:CreativeWork
    240 https://doi.org/10.1200/jco.2005.03.3845 schema:sameAs https://app.dimensions.ai/details/publication/pub.1064204218
    241 rdf:type schema:CreativeWork
    242 https://doi.org/10.1200/jco.2009.25.1991 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019828190
    243 rdf:type schema:CreativeWork
    244 https://doi.org/10.1371/journal.pone.0075414 schema:sameAs https://app.dimensions.ai/details/publication/pub.1039471372
    245 rdf:type schema:CreativeWork
    246 https://doi.org/10.1517/14712590903319656 schema:sameAs https://app.dimensions.ai/details/publication/pub.1067588039
    247 rdf:type schema:CreativeWork
    248 https://doi.org/10.1517/14728222.2010.519701 schema:sameAs https://app.dimensions.ai/details/publication/pub.1019091862
    249 rdf:type schema:CreativeWork
    250 https://doi.org/10.4049/jimmunol.170.9.4854 schema:sameAs https://app.dimensions.ai/details/publication/pub.1075280428
    251 rdf:type schema:CreativeWork
    252 https://doi.org/10.4161/cbt.6.9.4905 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072294727
    253 rdf:type schema:CreativeWork
    254 https://doi.org/10.7554/elife.30224 schema:sameAs https://app.dimensions.ai/details/publication/pub.1100468486
    255 rdf:type schema:CreativeWork
    256 https://www.grid.ac/institutes/grid.417768.b schema:alternateName Center for Cancer Research
    257 schema:name Women’s Malignancies Branch, Center for Cancer Research, National Cancer Institute, Building 10, Room 4B54, 20892-1361, Bethesda, MD, USA
    258 rdf:type schema:Organization
    259 https://www.grid.ac/institutes/grid.418152.b schema:alternateName AstraZeneca (United States)
    260 schema:name MedImmune, LLC, Gaithersburg, MD, USA
    261 rdf:type schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...